Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 27
- Registration Number
- NCT06625190
Romosozumab As an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT06533865
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT06374459
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 1360
- Registration Number
- NCT06221072
Sequential Therapies After Osteoanabolic Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06164795
- Locations
- 🇩🇪
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
🇬🇷251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Aksaray University
- Target Recruit Count
- 20
- Registration Number
- NCT06135298
- Locations
- 🇹🇷
Aksaray University Training and Research Hospital, Aksaray, Turkey
The Optimised Use of Romozosumab Study
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 270
- Registration Number
- NCT06059222
- Locations
- 🇩🇰
Department of Endrocinology and Internal Medicine, Aarhus, Denmark
Effect of Zoledronic Acid in Primary Knee Osteoarthritis
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Toufiqe-E-Ealahi
- Target Recruit Count
- 92
- Registration Number
- NCT06051344
- Locations
- 🇧🇩
Department of rheumatology, Dhaka, Shahbag, Bangladesh
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 264
- Registration Number
- NCT05866172
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 2692
- Registration Number
- NCT05743179
- Locations
- 🇭🇰
Caritas Medical Centre, Sham Shui Po, Hong Kong
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
🇭🇰United Christian Hospital, Kwun Tong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.